- Home
- PTON vs ZLAB Comparison
PTON vs ZLAB Comparison
Compare PTON & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTON
- ZLAB
- Stock Information
- Founded
- PTON 2012
- ZLAB 2013
- Country
- PTON United States
- ZLAB China
- Employees
- PTON N/A
- ZLAB N/A
- Industry
- PTON Recreational Games/Products/Toys
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PTON Consumer Discretionary
- ZLAB Health Care
- Exchange
- PTON Nasdaq
- ZLAB Nasdaq
- Market Cap
- PTON 3.6B
- ZLAB 3.4B
- IPO Year
- PTON 2019
- ZLAB 2017
- Fundamental
- Price
- PTON $8.56
- ZLAB $33.78
- Analyst Decision
- PTON Hold
- ZLAB Strong Buy
- Analyst Count
- PTON 19
- ZLAB 3
- Target Price
- PTON $7.55
- ZLAB $55.00
- AVG Volume (30 Days)
- PTON 17.6M
- ZLAB 752.8K
- Earning Date
- PTON 02-06-2025
- ZLAB 02-27-2025
- Dividend Yield
- PTON N/A
- ZLAB N/A
- EPS Growth
- PTON N/A
- ZLAB N/A
- EPS
- PTON N/A
- ZLAB N/A
- Revenue
- PTON $2,621,100,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- PTON N/A
- ZLAB $49.04
- Revenue Next Year
- PTON $1.11
- ZLAB $46.80
- P/E Ratio
- PTON N/A
- ZLAB N/A
- Revenue Growth
- PTON N/A
- ZLAB 35.01
- 52 Week Low
- PTON $2.70
- ZLAB $13.48
- 52 Week High
- PTON $10.90
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- PTON 47.25
- ZLAB 79.95
- Support Level
- PTON $8.54
- ZLAB $30.61
- Resistance Level
- PTON $10.02
- ZLAB $33.00
- Average True Range (ATR)
- PTON 0.67
- ZLAB 1.32
- MACD
- PTON 0.09
- ZLAB 0.58
- Stochastic Oscillator
- PTON 44.77
- ZLAB 86.34
About PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of bike and tread and related accessories sales, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue is generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from the International markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.